Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
A Joint WHO/National Institute of Allergy and Infectious Diseases (NIAID) meeting on the current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development was held in Bethesda, MD, from 30 September to 1 October 1996. The meeting summarized the worldwide impact of RSV and PIV3; presented the current status of development of RSV and PIV3 vaccines; and examined the applications of recombinant DNA technology to the development and characterization of vaccines and to the understanding of viral pathogenesis.
Murphy
B R
BR
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, Bethesda, MD, USA.
Collins
P L
PL
D000328:Adult; D018076:DNA, Complementary / Q000235:genetics; D004274:DNA, Recombinant; D004279:DNA, Viral / Q000235:genetics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D009154:Mutation; D009316:National Institutes of Health (U.S.); D010224:Parainfluenza Virus 3, Human / Q000235:genetics / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000235:genetics / Q000276:immunology*; D018108:Respirovirus / Q000276:immunology; D014481:United States; D014613:Vaccines, Attenuated; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology; D014944:World Health Organization
D018076:DNA, Complementary; D004274:DNA, Recombinant; D004279:DNA, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines